Document detail
ID

oai:pubmedcentral.nih.gov:1011...

Topic
Antiviral Agents
Author
Marzinke, Mark A. Fogel, Jessica M. Wang, Zhe Piwowar-Manning, Estelle Kofron, Ryan Moser, Amber Bhandari, Pradip Gollings, Ryann Bushman, Lane R. Weng, Lei Halvas, Elias K. Mellors, John Anderson, Peter L. Persaud, Deborah Hendrix, Craig W. McCauley, Marybeth Rinehart, Alex R. St Clair, Marty Ford, Susan L. Rooney, James F. Adeyeye, Adeola Chariyalertsak, Suwat Mayer, Kenneth Arduino, Roberto C. Cohen, Myron S. Grinsztejn, Beatriz Hanscom, Brett Landovitz, Raphael J. Eshleman, Susan H.
Langue
en
Editor

American Society for Microbiology

Category

Antimicrobial Agents and Chemotherapy

Year

2023

listing date

9/21/2023

Keywords
083 tdf-ftc insti administration hptn arm hiv testing resistance
Metrics

Abstract

HPTN 083 demonstrated that injectable cabotegravir (CAB) was superior to oral tenofovir disoproxil fumarate-emtricitabine (TDF-FTC) for HIV prevention in cisgender men and transgender women who have sex with men.

We previously analyzed 58 infections in the blinded phase of HPTN 083 (16 in the CAB arm and 42 in the TDF-FTC arm).

This report describes 52 additional infections that occurred up to 1 year after study unblinding (18 in the CAB arm and 34 in the TDF-FTC arm).

Retrospective testing included HIV testing, viral load testing, quantification of study drug concentrations, and drug resistance testing.

The new CAB arm infections included 7 with CAB administration within 6 months of the first HIV-positive visit (2 with on-time injections, 3 with ≥1 delayed injection, and 2 who restarted CAB) and 11 with no recent CAB administration.

Three cases had integrase strand transfer inhibitor (INSTI) resistance (2 with on-time injections and 1 who restarted CAB).

Among 34 CAB infections analyzed to date, diagnosis delays and INSTI resistance were significantly more common in infections with CAB administration within 6 months of the first HIV-positive visit.

This report further characterizes HIV infections in persons receiving CAB preexposure prophylaxis and helps define the impact of CAB on the detection of infection and the emergence of INSTI resistance.

Marzinke, Mark A.,Fogel, Jessica M.,Wang, Zhe,Piwowar-Manning, Estelle,Kofron, Ryan,Moser, Amber,Bhandari, Pradip,Gollings, Ryann,Bushman, Lane R.,Weng, Lei,Halvas, Elias K.,Mellors, John,Anderson, Peter L.,Persaud, Deborah,Hendrix, Craig W.,McCauley, Marybeth,Rinehart, Alex R.,St Clair, Marty,Ford, Susan L.,Rooney, James F.,Adeyeye, Adeola,Chariyalertsak, Suwat,Mayer, Kenneth,Arduino, Roberto C.,Cohen, Myron S.,Grinsztejn, Beatriz,Hanscom, Brett,Landovitz, Raphael J.,Eshleman, Susan H., 2023, Extended Analysis of HIV Infection in Cisgender Men and Transgender Women Who Have Sex with Men Receiving Injectable Cabotegravir for HIV Prevention: HPTN 083, American Society for Microbiology

Document

Open Open

Share

Source

Articles recommended by ES/IODE AI

Batoclimab as induction and maintenance therapy in patients with myasthenia gravis: rationale and study design of a phase 3 clinical trial
gravis myasthenia study clinical phase baseline improvement mg-adl 340 week trial placebo period mg maintenance qw